1,699 reports of this reaction
1.6% of all CYTARABINE reports
#20 most reported adverse reaction
MUCOSAL INFLAMMATION is the #20 most commonly reported adverse reaction for CYTARABINE, manufactured by Fresenius Kabi USA, LLC. There are 1,699 FDA adverse event reports linking CYTARABINE to MUCOSAL INFLAMMATION. This represents approximately 1.6% of all 108,092 adverse event reports for this drug.
Patients taking CYTARABINE who experience mucosal inflammation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MUCOSAL INFLAMMATION is a less commonly reported adverse event for CYTARABINE, but still significant enough to appear in the safety profile.
In addition to mucosal inflammation, the following adverse reactions have been reported for CYTARABINE:
The following drugs have also been linked to mucosal inflammation in FDA adverse event reports:
MUCOSAL INFLAMMATION has been reported as an adverse event in 1,699 FDA reports for CYTARABINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MUCOSAL INFLAMMATION accounts for approximately 1.6% of all adverse event reports for CYTARABINE, making it a notable side effect.
If you experience mucosal inflammation while taking CYTARABINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.